Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy
Tm. Soergel et al., Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy, J UROL, 166(6), 2001, pp. 2198-2201
Purpose: We determined how prostate specific antigen (PSA) doubling time ch
anged with time and whether an early measure of doubling time would accurat
ely predict long-term PSA values and clinical outcome in a cohort of patien
ts followed expectantly after radical prostatectomy.
Materials and Methods: We analyzed data on 121 patients with PSA recurrence
after radical retropubic prostatectomy. Group and individual analyses were
performed on 60 patients who met study inclusion criteria. PSA doubling ti
me was calculated and a curve was plotted using logarithmic transformation
with linear regression and least squares analysis. In analysis 1 patients w
ere placed into 3 subgroups according to doubling time. Doubling time was c
alculated per subgroup and the slopes of the aggregate curves were compared
to determine how doubling time changed with time. In analysis 2 we calcula
ted early doubling time per patient using only the initial 2 detectable PSA
values and compared it with eventual doubling time in each using all PSA v
alues. In addition, we analyzed how doubling time correlated with the clini
cal course.
Results: Using the group methodology there was no statistically significant
acceleration or deceleration with time in doubling time slope in any of th
e 3 subgroups. On individual analysis we noted a weak correlation of early
with eventual doubling time (correlation coefficient 0.69, p = 0.01). In 88
% of patients eventual doubling time was not within 10%, of early doubling
time. Metastasis developed in 60% of patients with an eventual DT of 0 to 6
months, while 80% with an eventual doubling time of 6 to 12 months had no
evidence of local or metastatic disease. No patients with an eventual doubl
ing time of greater than 12 months have had metastatic disease and only 4 (
16%) had local recurrence, which was treated with radiation therapy. In 8 o
f the 14 patients (23%) with local recurrence or metastatic disease early d
oubling time predicted eventual doubling time. Early doubling time was more
rapid and slower than eventual doubling time in 5 and 1, respectively, of
the remaining cases, which would have placed them in a different subgroup.
Conclusions: On group analysis PSA doubling time appeared to be constant wi
th time and there was no evidence that it accelerated with time in our data
set of PSA recurrence after radical prostatectomy. On individual analysis e
arly doubling time showed a weak but statistically significant correlation
with eventual doubling time. However, there was significant inaccuracy when
predicting PSA doubling time based on early PSA values in individuals. Gen
erally early projections of doubling time tend to over predict tumor biolog
ical aggressiveness, that is local recurrence or metastasis. A need remains
for more accurate predictors of the rate of disease progression at initial
PSA recurrence to determine accurately early in the clinical course the pa
tients who may benefit from additional therapy. Currently no patient in our
study has died of prostate cancer.